Valuation: Intervacc AB

Market Cap 370M 39.09M 33.48M 31.33M 28.68M 53.82M 3.74B 54.53M 144M 1.88B 147M 144M 6.21B P/E 2026 *
-4.53x
P/E 2027 * -4.53x
Enterprise Value 281M 29.69M 25.43M 23.79M 21.78M 40.88M 2.84B 41.42M 110M 1.43B 111M 109M 4.72B EV / Sales 2026 *
13.3x
EV / Sales 2027 * 10.3x
Free-Float
80.66%
Yield 2026 *
-
Yield 2027 * -
1 day-1.63%
1 week-9.35%
Current month-14.49%
1 month-4.57%
3 months-8.12%
6 months+52.96%
Current year+17.53%
1 week 1
Extreme 0.999
1.2
1 month 1
Extreme 0.999
1.35
Current year 0.57
Extreme 0.572
1.46
1 year 0.57
Extreme 0.572
1.46
3 years 0.57
Extreme 0.572
10.46
5 years 0.57
Extreme 0.572
77.8
10 years 0.57
Extreme 0.572
95.5
Manager TitleAgeSince
Chief Executive Officer 70 2026-02-04
Director of Finance/CFO - 2020-02-05
Chief Tech/Sci/R&D Officer - 2020-06-10
Director TitleAgeSince
Chairman 56 2026-05-12
Director/Board Member 72 2023-12-31
Director/Board Member 68 2024-12-31
Date Insider Type Main position Quantity % Market Cap.
2/23/25 Free

Chief Financial Officer

929,208 1.2269%
2/17/25 Buy

Chief Executive Officer

135,000 0.1783%
2/17/25 Sell

Chief Executive Officer

278,820 0.3681%
Change 5-day change 1-year change 3-year change Capi.($)
-1.63%-9.35%+6.47%-75.76% 39.09M
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +0.96%+6.59%+54.60%+169.57% 28.95B
Weighted average by Cap. +0.74%+9.48%+59.04%+157.77%

Financials

2026 *2027 *
Net sales 21.1M 2.23M 1.91M 1.79M 1.63M 3.07M 213M 3.11M 8.23M 107M 8.37M 8.18M 354M 30.05M 3.17M 2.72M 2.54M 2.33M 4.37M 304M 4.43M 11.72M 153M 11.92M 11.66M 504M
Net income -82.45M -8.71M -7.46M -6.98M -6.39M -11.99M -833M -12.15M -32.15M -418M -32.69M -31.98M -1.38B -83.65M -8.83M -7.57M -7.08M -6.48M -12.16M -845M -12.32M -32.62M -425M -33.17M -32.45M -1.4B
Net Debt -89M -9.4M -8.05M -7.53M -6.9M -12.94M -899M -13.11M -34.71M -452M -35.29M -34.52M -1.49B -61M -6.44M -5.52M -5.16M -4.73M -8.87M -616M -8.99M -23.79M -310M -24.19M -23.66M -1.02B
Logo Intervacc AB
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company’s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
Employees
16
Date Price Change Volume
26-08-21 SEK 1.086 -1.63% 510,315
26-08-20 SEK 1.104 -1.08% 1,622,305
26-08-19 SEK 1.116 -2.96% 235,611
26-08-18 SEK 1.150 -1.71% 460,588
26-08-17 SEK 1.170 -2.34% 329,577

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IVACC Stock